产品
编 号：F741316
分子式：C22H25F3N4O3
分子量：450.45
分子式：C22H25F3N4O3
分子量：450.45
产品类型
规格
价格
是否有货
结构图
CAS No: 1931994-80-7
产品详情
生物活性：
IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research.
体内研究：
IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice.Animal Model:Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model
Dosage:150 mg/kg
Administration:Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling
Result:Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF. Effectively reduced the numbers of total T cells, monocyte, and macrophages. Largely preserved the signatures of na?ve lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells. Regulated inflammation and innate immunity genes more efficiently than Dexamethasone (HY-14648).
体外研究：
IRAK4-IN-20 (Compound BAY-1834845) (500 nM, 20 h) decreases inflammatory cytokines secretion effectively in an in vitro treatment of LPS stimulated human peripheral blood mononuclear cells (PBMC).
IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research.
体内研究：
IRAK4-IN-20 (Compound BAY-1834845) (150 mg/kg; p.o.; once or twice) effectively prevents acute respiratory distress syndrome in mice.Animal Model:Female Balb/c mice (aged 6–7 weeks), LPS-induced ARDS mouse model
Dosage:150 mg/kg
Administration:Oral administration, 30 min before LPS modeling or twice 4 h and 12 h after LPS modeling
Result:Remarkably decreased inflammatory cells infiltrating lung tissue and neutrophil count in BALF. Effectively reduced the numbers of total T cells, monocyte, and macrophages. Largely preserved the signatures of na?ve lymphocytes and stromal cells such as endothelial cells, chondrocytes, and smooth muscle cells. Regulated inflammation and innate immunity genes more efficiently than Dexamethasone (HY-14648).
体外研究：
IRAK4-IN-20 (Compound BAY-1834845) (500 nM, 20 h) decreases inflammatory cytokines secretion effectively in an in vitro treatment of LPS stimulated human peripheral blood mononuclear cells (PBMC).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备